Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Collegium Pharmaceutical (COLL) Acquisitions (2018 - 2022)

Collegium Pharmaceutical has reported Acquisitions over the past 2 years, most recently at $572.1 million for Q1 2022.

For Q1 2022, Acquisitions changed N/A year-over-year to $572.1 million; the TTM value through Dec 2022 reached $572.1 million, changed N/A, while the annual FY2024 figure was $267.5 million, N/A changed from the prior year.
Acquisitions for Q1 2022 was $572.1 million at Collegium Pharmaceutical, up from $116000.0 in the prior quarter.
Over five years, Acquisitions peaked at $572.1 million in Q1 2022 and troughed at $116000.0 in Q2 2018.